Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Trial Profile

Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Erythema
  • Focus Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Allergan
  • Most Recent Events

    • 30 Jan 2018 Primary endpoint (Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales) has been met as per the results published in the Journal of the American Academy of Dermatology
    • 30 Jan 2018 Results (n=885) of pooled analysis of REVEAL 1 and REVEAL 2 trials assessing safety and efficacy published in the Journal of the American Academy of Dermatology
    • 24 May 2017 Results from this and one other study (NCT02131636) assessing the Impact Assessment for Rosacea Facial Redness (IA-RFR) outcome, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top